BSBeenish Mbbs Sabir

Beenish Mbbs Sabir

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Beenish Mbbs Sabir has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Concurrent postpartum cerebral venous thrombosis and acute toxoplasmosis–debut of a unique clinical convergence: a case report

    by Shafaq Saleem, Muhammad Haroon, Ahmad Raza, Azeen Razzaq, Beenish Sabir, Shaheem Ur Rehman, Muhammad Usman Iqbal, Fatima Hajj

    Introduction and importance: Cerebral venous thrombosis (CVT) is a rare but serious condition, with pregnancy and puerperium representing major risk factors. Toxoplasma gondii typically causes asymptomatic infection in immunocompetent individuals. No case of concurrent postpartum CVT and acute toxoplasmosis has previously been reported. Case presentation: A 27-year-old woman presented 14 days postpartum with headache, fever, altered sensorium, and left-sided weakness. Neurological examination revealed a Glasgow Coma Scale score of 8/15 with focal deficits. Serology demonstrated positive Toxoplasma gondii IgM antibodies, indicating a recent infection. MRI/MRV confirmed multiple venous infarcts with hemorrhagic transformation, consistent with CVT. Protein C and S levels were reduced; however, these were interpreted cautiously, as acute thrombosis, systemic inflammation, and puerperium can transiently lower natural anticoagulant levels. Repeat testing post-recovery was planned. The patient was managed with anticoagulation, corticosteroids, and supportive care, followed by oral rivaroxaban and physiotherapy, achieving significant neurological recovery over 2 months. Clinical discussion: The concurrence of postpartum CVT and positive Toxoplasma gondii serology is unprecedented. Pregnancy-related hypercoagulability, compounded by infection-induced endothelial dysfunction, likely contributed to thrombosis. Reduced Protein C and S levels, measured during acute thrombosis or puerperium, may not reflect inherited deficiency; repeat testing after anticoagulation completion is necessary before diagnosing congenital deficiency. Anticoagulation, per international guidelines, remained the cornerstone of management and proved effective despite hemorrhagic infarcts. Conclusion: This first documented case of postpartum CVT with concurrent Toxoplasma gondii serology suggestive of recent infection underscores the importance of prompt recognition and timely anticoagulation.

  • Open Access

    Recurrent nasal bleed as initial presenting complaint: a rare complication of giant prolactinoma in a 39-year-old

    by Wajeeha Mbbs Fahim, Matiullah Mbbs Kamin, Laiba Mbbs Sultan, Beenish Mbbs Sabir, Muhammad Usman Mbbs Iqbal, Fatima Hajj

    Introduction and importance: Giant prolactinoma is a rare endocrine disorder that presents with unusually large size and markedly high serum prolactin levels. The objective of this report is to show the aggressive invasive nature of giant prolactinoma with rare clinical presentation of recurrent nasal bleeds and the use of cabergoline in the successful management of patients having severe symptoms of extreme headaches and bitemporal hemianopia along with intracranial invasion of tumor. Case presentation: A 39-year-old married Asian male, presented with severe headaches, blurred vision in the left eye, and recurring nasal bleeding. Perimetry revealed bitemporal hemianopia. MRI showed a well-defined mass in the sellar/suprasellar region (3.7 × 4.0 × 3.8 cm). Initial prolactin levels were >4000 ng/ml and testosterone levels were 69 ng/dl (300–890 ng/dl). The patient after being diagnosed with Giant Prolactinoma started treatment with cabergoline which reduced prolactin levels to 14 ng/ml and the mass to 1.7 × 1.9 × 1.4 cm, though testosterone levels remained low at 134 ng/dl. Clinical discussion: Giant prolactinomas present significant diagnostic and therapeutic challenges due to their size, invasiveness, and resistance to conventional treatments. This case report demonstrates the successful management of a giant prolactinoma, treated initially with cabergoline that effectively reduced prolactin levels and tumor size, highlighting its role as a first-line therapy. Comprehensive management involved adjusting cabergoline dosage and introducing testosterone replacement therapy for hypogonadism. Conclusion: In conclusion, managing giant prolactinomas requires a multidisciplinary approach, with dopamine agonists as the cornerstone of treatment. Individualized strategies, adjunctive therapies, and regular monitoring ensure comprehensive care.